I-Team: Cleveland schools CEO dodges questions on travel costs
But district CEO Warren Morgan dodged most of our questions.
School taxes in Cleveland just went up. Voters approved a levy in November.
But according to public records obtained by the I-Team, the district spent nearly a $1 million on travel in just one year.
Student loan borrowers could see 'massive' payment spikes
The I-Team has tried for months to talk to Morgan. We've tried arranging something through district spokespersons, yet the CEO has never sat down with us. In fact, last year, we had an interview arranged and at the last minute, the district canceled.
So we went to a school board meeting Tuesday and we tried to speak to the CEO before the meeting started.
'We'd like to get a word with you. We've been trying for months,' I-Team Reporter Ed Gallek said.
Morgan did not stop and talk to us. Instead, he opened a door and walked into a room where all school board members were gathered prior to the start of the meeting.
One woman yelled and said we were interrupting a meeting. When the I-Team asked why board members were meeting in private without calling an executive session, the school board attorney said the members were eating prior to the meeting and not discussing official business.
We recently showed you that in one year Cleveland schools spent more than $855,000 sending employees on trips out of state. The district sent well over 100 people to one conference. Even secretaries have gone on trips.
We asked the CEO why he keeps avoiding us. But he said, 'We're not avoiding.'
The records also show the CEO took nine trips, even as the district put out a desperate call for more tax money.
During our encounter, Morgan said, 'Right now, we're about to start our Board meeting. I'll talk to you later.'
We responded with, 'What's later? Because you've never done it.'
We turned to Polly Karr, a mother and school district watchdog.
'I'd like them to stop traveling,' she said.
She wants smarter spending now, with higher taxes.
'I wouldn't mind paying it if it was going to the students, to the classroom,' Karr added. 'Cleveland students need more. I want to see the kids get stuff instead of the administrators.'
The I-Team also has been trying to ask about district travel going forward.
Cleveland schools sent 118 people last year to the Model Schools Conference. So, what about this year?
We asked the CEO, 'For the Model Conference, are you changing anything this year for the Model Conference?'
Morgan responded with, 'We can talk later. We have a board meeting.'
'Dried blood, dirty pawprints:' Local vet arrested, 110 animals seized
Weeks ago, a district official promised tighter controls over travel. On Tuesday, Morgan referred to that but did not offer any specifics.
'Since we've put in our travel restrictions, all of our costs have actually decreased. But we're about to start a meeting,' he said.
Weeks ago, Lisa Farmer Cole, chief external affairs officer, answered questions about more than 100 people from Cleveland schools going to one conference. She said,
'So I think of that 118, about 16 were principals and assistant principals. And, about 100 teachers went. So, that is a conference that is chock-full of best practices. School districts from all over the country go to the Model Schools Conference because this is about model schools.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
an hour ago
- Associated Press
I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study Median follow-up of 9.0 months as of the updated data cutoff Responses observed in patients with low PD-L1 and/or CLDN18.2 expression Company to host investor event on Tuesday, July 8th ROCKVILLE, Md., July 02, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the presentation of positive Phase 1b combination data for givastomig, in combination with nivolumab and mFOLFOX6, at the European Society for Medical Oncology Gastrointestinal Cancers Congress 2025 (ESMO GI 2025) in Barcelona (abstract #388MO) . Givastomig is a bispecific antibody targeting Claudin 18.2 and 4-1BB. I-Mab plans to host a virtual investor event on Tuesday, July 8th (register here ) to review these data. The Phase 1b data (NCT04900818) show a confirmed objective response rate (ORR) of 71% across all doses (12/17), and 83% (10/12) at doses selected for the ongoing dose expansion study (8 mg/kg and 12 mg/kg). Responses occurred in tumors with low levels of PD-L1 expression and/or Claudin 18.2 (CLDN18.2) expression, with favorable overall tolerability. There were no Grade 3 or greater events for nausea and vomiting, and only one Grade 3 TRAE for increased liver enzymes. The data are based on the results of the dose escalation part of a Phase 1b study evaluating the givastomig combination as first line therapy (1L) in patients with Claudin 18.2-positive gastric cancers (≥1+ IHC staining intensity in ≥1% of tumor cells). The primary endpoint is safety. The study enrolled only patients in the U.S. 'The positive Phase 1b combination data presented at ESMO GI bolster our confidence in givastomig's potential to be a best-in-class Claudin 18.2 directed therapy. Givastomig has been well tolerated when combined with immuno-oncology and chemotherapy, has shown a high objective response rate, with rapid onset and durable responses that have deepened over time, supported by consistent pharmacokinetic data and soluble 4-1BB induction,' said Phillip Dennis, MD, PhD, Chief Medical Officer of I-Mab. 'In addition, we are optimistic about the results from the 8 mg/kg and 12 mg/kg doses. These doses showed an ORR of 83%, with consistent responses across PD-L1 and Claudin 18.2 expression levels, and a favorable overall safety profile. These data further our conviction in the ongoing Phase 1b dose expansion study. We believe givastomig has broad potential in a number of gastric cancer settings and look forward to continued advancement of the program.' 'I am encouraged by the response rates, as well as the deepening of responses over time, demonstrated by the givastomig combination regimen in the Phase 1b dose escalation study that we presented today at ESMO GI. Despite approved therapies, targeted treatment options for gastric cancers continue to be limited. While the data are early, givastomig combination therapy demonstrates a high response rate across Claudin 18.2 and PD-L1 expression levels,' said Samuel J Klempner, MD, Associate Professor of Medicine at Massachusetts General Hospital. 'In addition, I have been pleased to observe that givastomig has a favorable overall tolerability profile with a low level of gastrointestinal side effects -- especially important for patients with gastric cancer. I look forward to participating in the ongoing givastomig clinical development program, and hope we may be able to expand the population of patients who may benefit from Claudin 18.2 directed agents.' Virtual Investor Event: Register ( here ) for the Post-ESMO GI 2025 Investor Event to be held on Tuesday, July 8th at 2:00 PM EDT. A replay of the webinar will be accessible on the Events page of the I-Mab website for 90 days. Fireside Chat Event with Lucid Capital Markets to Recap the Presentation: Tune in ( here ) for a fireside chat sponsored by Christopher Liu, PharmD, Managing Director at Lucid Capital Markets that will be accessible today at 2:00pm EDT on the Events page of the I-Mab website. A replay of the fireside chat will be available for 90 days. ESMO GI Presentation Details: A full copy of the ESMO GI presentation is available on the Publications and Presentations page of the I-Mab website here. Givastomig Phase 1b Dose Escalation Data Summary in 1L Gastric Cancers Patient Characteristics: Efficacy Results: Durability: Safety: About Givastomig Givastomig (TJ033721 / ABL111) is a bispecific antibody targeting Claudin 18.2 (CLDN18.2)-positive tumor cells. It conditionally activates T cells through the 4-1BB signaling pathway in the tumor microenvironment where CLDN18.2 is expressed. Givastomig is being developed for first line (1L) metastatic gastric cancers, with further potential in other solid tumors. In Phase 1 trials, givastomig has shown promising anti-tumor activity attributable to a potential synergistic effect of proximal interaction between CLDN18.2 on tumor cells and 4-1BB on T cells in the tumor microenvironment, while minimizing toxicities commonly seen with other 4-1BB agents. An ongoing Phase 1b study is evaluating givastomig for the treatment of gastric cancer in the 1L setting in combination with standard of care, nivolumab (an anti-PD-1 checkpoint inhibitor) plus chemotherapy, in dose escalation and dose expansion cohorts. Dose escalation is complete, and enrollment in the first dose expansion cohort (n=20) finished ahead of schedule. Enrollment continues to progress ahead of schedule in the second dose expansion cohort (n=20). The study builds on positive Phase 1 monotherapy data. Givastomig is being jointly developed through a global partnership with ABL Bio, in which I-Mab is the lead party and shares worldwide rights, excluding Greater China and South Korea, equally with ABL Bio. About I-Mab I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. The Company's differentiated pipeline is led by givastomig, a potential best-in-class, bispecific antibody (Claudin 18.2 x 4-1BB) designed to treat Claudin 18.2-positive gastric cancers. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed for first-line metastatic gastric cancers, with additional potential in other solid tumors. In Phase 1 trials, givastomig was observed to maintain strong tumor-binding and anti-tumor activity, attributable to a potential synergistic effect of proximal interaction with Claudin 18.2 and 4-1BB, while minimizing toxicities commonly seen with other 4-1BB agents. For more information, please visit and follow us on LinkedIn and X. I-Mab Forward Looking Statements This announcement contains forward-looking statements. These statements are made under the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'will', 'expects', 'believes', 'designed to', 'anticipates', 'future', 'intends', 'plans', 'potential', 'estimates', 'confident', and similar terms or the negative thereof. I-Mab may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the SEC), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about I-Mab's beliefs and expectations, are forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the Company's pipeline and clinical development of I-Mab's drug candidates, including givastomig; the projected advancement of the Company's portfolio and anticipated milestones and related timing; the Company's expectations regarding the impact of data from ongoing and future clinical trials; the timing and progress of studies and trials (including with respect to patient enrollment); the potential benefits of givastomig; and the availability of data and information from ongoing studies and trials. Forward-looking statements involve inherent risks and uncertainties that may cause actual results to differ materially from those contained in these forward-looking statements, including but not limited to the following: I-Mab's ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may or may not support further development or New Drug Application/Biologics License Application (NDA/BLA) approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of I-Mab's drug candidates; I-Mab's ability to achieve commercial success for its drug candidates, if approved; I-Mab's ability to obtain and maintain protection of intellectual property for its technology and drugs; I-Mab's reliance on third parties to conduct drug development, manufacturing and other services; and I-Mab's limited operating history and I-Mab's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the 'Risk Factors' section in I-Mab's annual report on Form 20-F filed with the SEC on April 3, 2025, as well as the discussions of potential risks, uncertainties, and other important factors in I-Mab's subsequent filings with the SEC. All forward-looking statements are based on information currently available to I-Mab. I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. I-Mab Investor & Media Contacts PJ Kelleher LifeSci Advisors +1-617-430-7579 [email protected] [email protected]
The Hill
2 hours ago
- The Hill
Hogg's political group backs Gen Z influencer for open Arizona House seat
Leaders We Deserve, a political group founded by David Hogg and Kevin Lata, announced on Wednesday that it would be supporting Gen Z influencer Deja Foxx, who's running to succeed the late Rep. Raúl M. Grijalva (D-Ariz.). A special election to fill the remainder of his term is set for September, with a primary on July 15. 'Deja Foxx has been holding Republicans' and career politicians' feet to the fire since she was 15 years old. She's an organizer who has carved her own path after experiencing homelessness and working at a gas station — and she is ready to fight for Tuscon, her hometown,' Hogg said in a statement. Hogg noted, too, that she 'stood up to Arizona's former Republican Senator Jeff Flake' – referring to an exchange she had with Flake when she was 16 years old that later went viral in which she pressed him on reproductive care access. 'Deja knows people like her haven't been seen in politics, and she has translated her story to represent a new vision of generational change that speaks truth to Trump's cruel policies,' he added. Foxx, in her own statement, said she was 'excited' to work with the group as she faces a crowded primary field for the Democratic nod for Arizona's 7th Congressional District. 'I'm proud to be in this fight with Leaders We Deserve, an organization that understands the power of young people to transform politics and fight for communities that have been left out,' she said. Foxx is running to finish out the remainder of Grijalva's term in the House; Grijalva died in March at the age of 77 over complications of his cancer treatments. The late lawmaker's daughter, former Pima County Supervisor Adelita Grijalva, is also running in the Democratic primary, in addition to businessman Patrick Harris Sr.; former state Rep. Daniel Hernandez, who helped save former Rep. Gabby Giffords's (D-Ariz.) life after the 2011 Tucson-area shooting; and doctoral student José Malvido Jr. Former Pima County Supervisor Adelita Grijalva has enjoyed endorsements from top Democrats in the Grand Canyon State and beyond, including Sens. Mark Kelly and Ruben Gallego, Vermont progressive Sen. Bernie Sanders (I-Vt.) and Rep. Alexandria Ocasio-Cortez (D-N.Y.). Hernandez has received endorsements from a mix of former and current Arizona legislators, the Teamsters and several U.S. House members, among others. The special election to fill the seat will be Sept. 23; given the district's reliably blue leanings, whoever wins the July primary will be the heavy favorite to win in the fall.
Forbes
5 hours ago
- Forbes
Workplace Agility Is Vital During Disruption—So What Is It, Exactly?
Elaine Pulakos, Ph.D., is CEO of PDRI by Pearson, and an internationally recognized contributor to the field of I/O psychology. The workplace has undergone an extraordinary transformation in just the last four years. Pandemic-driven economic shocks threw entire industries into chaos, and remote work shifted from a rare exception to an expectation. Then generative AI took the world by storm, reshaping workflows and powering new, previously unthinkable capabilities. Now, political and economic changes at the global scale have led to sudden shifts that are disrupting individuals and organizations. But even before the pandemic touched off this current period of upheaval, businesses' technical skill requirements were already rapidly evolving. A 2021 Gartner study revealed that one-third of the technical skills listed in job postings for sales, finance and IT roles in 2017 had become obsolete by 2021. This trend has likely accelerated, creating a fundamental challenge: How can professionals remain valuable when technical competencies have increasingly shorter shelf lives? In this environment, employees need more than traditional skills to succeed. They need agility. In particular, they need a constellation of six specific power skills that enable them to thrive and perform effectively amid disruption, volatility and dramatic change. What Are Power Skills? Commonly referred to as soft skills, power skills are employees' durable, often innate capabilities that form the foundation for performing effectively across different roles and situations. They include skills like empathy, initiative, attention to detail and critical thinking. I prefer the term "power skills" because it emphasizes how important they are to employees' success. As disruptive change has increasingly characterized work settings, many of the power skills that matter have evolved. Consider interpersonal effectiveness. While the ability to collaborate and get along with colleagues remains important, today's workplace demands more sophisticated interpersonal intelligence. Modern professionals must quickly identify others' needs, accurately read situational cues and rapidly adjust their communication approaches and actions to achieve important outcomes. 6 Essential Characteristics Of Workplace Agility Multiple studies have noted the characteristics that collectively enable workplace agility. To perform successfully today, focusing on these key six will be vital. 1. Resilience: Employees need the ability to maintain composure under pressure and direct their energy toward constructive solutions, rather than becoming paralyzed by uncertainty. Resiliency allows them to absorb setbacks without becoming demoralized and maintain perspective during difficult circumstances. 2. Creative Problem-Solving: As the pace of change accelerates, established solutions often become obsolete quickly. Professionals with strong creative problem-solving capabilities can generate novel ideas and think beyond conventional parameters to develop innovative approaches. 3. Adaptability: Highly adaptable employees effectively adjust plans, goals and priorities in response to dynamic situations. They recognize when circumstances warrant course corrections and implement these adjustments, rather than sticking to an approach that's no longer working. 4. Continuous Learning: One of the most critical power skills today is the ability and willingness to engage in perpetual learning. This encompasses more than taking the time to learn additional skills. Today, employees must create their own insurance policy against obsolescence by proactively identifying emerging skills and taking steps to acquire them. 5. Interpersonal Savvy: Modern professional environments require interpersonal intelligence that goes beyond basic collegiality. Team members should be able to demonstrate keen insight into others' motivations and tailor their approach to effectively influence diverse stakeholders. In matrix organizations where formal authority is limited, interpersonal savvy often determines who can mobilize resources that will enable initiatives' success. 6. Cultural Versatility: As organizations become increasingly global, cultural versatility has emerged as a critical capability. But it's more than the ability to work with people from different backgrounds. Culturally versatile and intelligent employees take conscious, deliberate action to understand other cultures' needs, customs and values. They also recognize how their own cultural conditioning influences their assumptions and actively work to expand their cultural intelligence. In a world where the only certainty is change, agility isn't just an advantage. It's essential for survival and success. By prioritizing the identification and development of workplace agility, forward-thinking companies will be able to evolve with the pace of change. In fact, the organizations that thrive will be able to actively shape any change to their advantage. Forbes Human Resources Council is an invitation-only organization for HR executives across all industries. Do I qualify?
